Special Issue "Basic and Translational Research on Cancer Immunology and Immunotherapy – Selection Papers from The 8^th Symposium on Advances in Cancer Immunology and Immunotherapy (SACII)"

Dear Colleagues,

The approval of immune checkpoint inhibitors (ICIs), more than a decade ago, has offered a paradigm shift for cancer immunotherapy, inducing effective and long-lasting clinical responses for many patients suffering from various types of cancer. Since that time, a combination of ICIs with other treatment modalities including cellular therapies, molecular targeted therapies, and cancer vaccines have provided added values expanding the impact of immunotherapies for cancer. Despite this success, many patients are refractive to immunotherapies, which highlights the need for finding ways to predict patient clinical responses to treatment. The 8^th Symposium on Advances in Cancer Immunology and Immunotherapy (SACII) (http://www.sacii-greece.org) which will hold on 1–3 December 2022 in Athens is focused on the most recent advances in immuno-oncology. The SACII was an interactive meeting which was planned to include multidisciplinary issues of cancer immunology and immunotherapy spanning basic and translational research with the ultimate goal of the design of the most effective cancer therapeutic strategies. The topics discussed aimed at the improvement of our understanding of methods to harness the adaptive as well as the innate immune system to fight against cancer progression. The scientific program was designed to expand our knowledge of (a) predictive biomarkers for cancer immunotherapies; (b) improvements on mechanisms of action for immunotherapeutic treatments in the treatment of malignancy; (c) results from clinical trials investigating the efficacy and safety of cancer immunotherapy regimens; and (d) strategies for immunomodulation, counteracting resistance and mitigating adverse events. The conference featured world-renowned national and international oncologists and researchers who are experts in basic and translational research and clinical trials, who provided their insights into the topics above in an effort to better understand tumor evolution and design improved treatment strategies. Our Special Issue will publish research and clinical studies which were presented during this conference.

Dr. Constantin N. Baxevanis
Dr. Ioannis Pateras
Prof. Dr. Jörg Wischhusen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.